Compare LPG & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPG | NBTX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2014 | 2018 |
| Metric | LPG | NBTX |
|---|---|---|
| Price | $43.77 | $39.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $39.33 | $36.00 |
| AVG Volume (30 Days) | ★ 605.2K | 115.0K |
| Earning Date | 05-21-2026 | 03-31-2026 |
| Dividend Yield | ★ 8.26% | N/A |
| EPS Growth | ★ 112.15 | N/A |
| EPS | ★ 4.54 | N/A |
| Revenue | ★ $481,511,242.00 | N/A |
| Revenue This Year | $35.73 | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.12 | ★ N/A |
| Revenue Growth | ★ 36.27 | N/A |
| 52 Week Low | $23.76 | $6.90 |
| 52 Week High | $48.12 | $57.14 |
| Indicator | LPG | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.